The critical decisions where clinical depth and commercial rigour change the answer
What Foundry gets called for
Healthcare strategy often fails at the intersection of clinical, commercial, and regulatory complexity. The commercial story has to survive the clinic; the clinical plan has to survive the boardroom; the strategy has to survive the regulator and the payer. These are six decisions we are commonly called in for.
1
Investment thesis stress-test on clinical adoption
When asset value depends on doctor adoption (whether they use the product, refer to the platform, or join the workforce), we stress-test the adoption story against how the relevant clinicians actually decide. We surface where the thesis is fragile and what it takes to hold.
Outcome: An IC-ready thesis where adoption risks are priced in, and value-creation levers are surfaced before commitment
2
Clinically-led commercial due diligence
When a target's thesis rests on clinical assumptions (adoption, workforce, referral dynamics, regulatory exposure, payer behaviour), we stress-test it with the clinicians who would actually deliver it. The clinical questions get answered in the diligence room.
Outcome: An IC decision that holds up to challenging and nuanced healthcare operational and cultural realities
3
Healthcare adoption strategy
When a new service line, workforce model, technology deployment, or operating model redesign needs clinical buy-in, we assess whether the change will take at the point of care, where it will resist, and what it takes to succeed. We give you a clear view of whether the bet has a realistic path with internal stakeholders.
Outcome: A board view of whether an initiative is implementable as designed, with the implementation risks identified and mitigated
4
Strategy at the intersection
When a decision sits at the intersection of 1) competition, 2) regulation, 3) funding, 4) clinician willingness, and 5) patient willingness, getting any one wrong unwinds the strategy. We frame the trade-offs across all five and identify the best path forward.
Outcome: A board strategy that survives contact with all five forces
5
Real-world market assessment
When a launch, service-line expansion, tech deployment, or value-creation plan rests on an adoption curve, we map the gap between stated demand and observed behaviour. Stated intent overestimates real adoption by 30 to 70 per cent in most healthcare settings. We uncover the path from real-world friction to clinical adoption and patient outcomes.
Outcome: A board-ready adoption forecast grounded in observed clinician behaviour
6
Regulatory and funding shift impact on strategy
When regulation or funding shifts re-rate the thesis (funding policy reform, fee-schedule change, payer model migration, compliance enforcement, accreditation shifts), we model the strategic and P&L impact, surface the levers, and frame the call: defend, reposition, lobby, or exit.
Outcome: A board view of how the regulatory shift reshapes the strategic landscape
If you're organisation is facing similar decisions and challenges, reach out to us for a discussion
Foundry specialises in strategic healthcare mandates. While we are always willing to discuss ways we can support, including introductions to more suitable partners and teams, we generally are not the right partner to lead change management, PMO work, pure IT consulting, and non-health care projects.